1,272 reports of this reaction
2.9% of all MELPHALAN HYDROCHLORIDE reports
#3 most reported adverse reaction
FEBRILE NEUTROPENIA is the #3 most commonly reported adverse reaction for MELPHALAN HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 1,272 FDA adverse event reports linking MELPHALAN HYDROCHLORIDE to FEBRILE NEUTROPENIA. This represents approximately 2.9% of all 43,335 adverse event reports for this drug.
Patients taking MELPHALAN HYDROCHLORIDE who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is a less commonly reported adverse event for MELPHALAN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to febrile neutropenia, the following adverse reactions have been reported for MELPHALAN HYDROCHLORIDE:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 1,272 FDA reports for MELPHALAN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 2.9% of all adverse event reports for MELPHALAN HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience febrile neutropenia while taking MELPHALAN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.